Aerovate Therapeutics (NASDAQ:JBIO) Upgraded by Guggenheim to Buy Rating
Guggenheim upgraded shares of Aerovate Therapeutics (NASDAQ:JBIO – Free Report) from a neutral rating to a buy rating in a research report released on Monday, MarketBeat.com reports. The firm currently has $14.00 price target on the stock. Separately, Wall Street Zen upgraded shares of Aerovate Therapeutics to a “hold” rating in a research report on […]
Guggenheim upgraded shares of Aerovate Therapeutics (NASDAQ:JBIO – Free Report) from a neutral rating to a buy rating in a research report released on Monday, MarketBeat.com reports. The firm currently has $14.00 price target on the stock. Separately, Wall Street Zen upgraded shares of Aerovate Therapeutics to a “hold” rating in a research report on […]
